by Rod Raynovich | Mar 30, 2010 | BIOgraph
US Judge invalidates cancer gene patents Intellectual Property (IP) is the raw material for the creation of biotech companies. Without an invention covered by a robust patent portfolio, venture funding can be very difficult. Since the beginning of the “genomic...
by Rod Raynovich | Mar 25, 2010 | BIOgraph, Energy, Macro
The market reversed today about 1:30p EDT as positive Bernanke chat yielded to Trichet and the Baklava Bailout. The NASDAQ Comp was up to the 2430 range then closed at 2397. The Rayno Life Science Index of 34 mid-cap biotechs was up 1.7% with 32 greens at 1:30p then...
by Rod Raynovich | Mar 23, 2010 | 2023-24 Life Science Portfolios, BIOgraph
The Raygent Model Portfolio was created in February 2009 and will be updated by the end of March 2010.The 14 month YTD performance is up 25%. New buys over past four months were Sequenom (SQNM) and SeraCare (SRLS). Currently under review are Immucor (BLUD) ,...
by Rod Raynovich | Mar 22, 2010 | BIOgraph
Healthcare and biotech stocks were up today as expected following passage of the historic reform bill. Although there is a considerable amount of work to be done in enabling the historic legislation, uncertainty has been removed and the market can play it out. Many...
by Rod Raynovich | Mar 18, 2010 | BIOgraph
We are currently rebalancing our 2010 Life Science Portfolio (See under “Articles” at top of WEB site). We are updating our Diagnostics and Genomics Model Portfolio as follows: Our winners for a 14 month period YTD are Abaxis (ABAX),Hologic (HOLX),...
by Rod Raynovich | Mar 18, 2010 | BIOgraph
Sequenom is finding price support today at $5.75, volume of 4.6M at 1p, after a severe three day downdraft triggered by their earnings release. Net loss for Q4 was $18.4M on Revenues of $10.8M. Cash position is $42M. Some pundits didn’t like the inability of...
by Rod Raynovich | Mar 15, 2010 | BIOgraph
Helicos made a timely entrance in the race for genetic analysis systems with their HeliScope “true single molecule sequencer” (tSMS), “the first DNA microscope”. The technology was positioned as an alternative to DNA amplification, requiring...
by Rod Raynovich | Mar 9, 2010 | BIOgraph
The FDA Panel of lung experts voted 9-3 in favor of approval of Intermune’s drug perfenidone for idiopathic pulmonary fibrosis. The stock was 15 at the end of February(see raygent.com last week) and reached 37 after hours tonite.. The IBB (biotech ETF) should...
by Rod Raynovich | Mar 9, 2010 | BIOgraph, Macro
There is a simple reason why healthcare reform is so hard to do-there has to be winners and losers. We have had many months of discussion on how to pay for healthcare reform such as cuts in Medicare, concessions from Big Pharma, more competition across state lines,...
by Rod Raynovich | Mar 5, 2010 | BIOgraph
The rally in biotech is back with lots of help from InterMune (ITMN).The stock was up over 60% to 23 this am after the Company posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee(PADAC) meeting to review the NDA for pirfenidone...
